Animal structural-repair findings and cellular pathway signals remain distinct from controlled human healing. The retrieved human pilots address local symptoms or short-term intravenous tolerability, rather than the exact systemic structural-healing claim.
This dated addendum adds selected evidence and tests that could resolve the remaining questions. It does not regrade the archived review.
Each question identifies a limit in the checked evidence. A missing search result alone does not establish a gap in the entire field.
Competing explanation: Symptoms may improve through analgesia, rehabilitation or natural recovery without faster structural repair.
Discriminating test: Registered randomized trial of a characterized product in objectively confirmed injury; identical rehabilitation, blinded imaging and mechanical/function endpoints.
Competing explanation: Animal cytoprotection or local bladder symptom relief may not translate to gastrointestinal re-epithelialization.
Discriminating test: Tissue-specific controlled trial with endoscopic/histological healing, systemic exposure confirmation and standard care held constant.
Competing explanation: Product heterogeneity or metabolite signal may be mistaken for sustained active-peptide exposure.
Discriminating test: Assay intact peptide and metabolites separately; establish batch identity, human PK, tissue-relevant PD and a prespecified exposure–response relation.
Competing explanation: Phosphorylation may be downstream repair activity; positive-study concentration may reflect reporting or laboratory effects.
Discriminating test: Independent preregistered injury-model replication, dose controls and pathway blockade/rescue with structural endpoints; report nulls and all planned outcomes.
Electronic publication dates are used where recorded, with issue years shown separately. This is a selected chronology, not a claim of scientific priority or independent replication for every entry.
BPC-157 improved reported functional, biomechanical and histological tendon outcomes.
What it cannot establish: Rodent injury and culture findings do not establish human systemic efficacy.
Intramuscular and intragastric dosing reduced injury and supported repair in the tested models.
What it cannot establish: Rat mucosal repair is not a controlled human gastrointestinal outcome.
Treatment improved healing measures and opposed corticosteroid aggravation.
What it cannot establish: Acute surgical injury differs from chronic human tendinopathy.
Treatment improved functional, biomechanical and histological measures.
What it cannot establish: Species, route and injury-model boundaries remain.
Outgrowth, migration and stress survival accompanied FAK/paxillin phosphorylation.
What it cannot establish: Pathway association is not a human healing-mediation test.
Treatment improved vascular and mucosal findings in selected injury models.
What it cannot establish: Mechanistic intervention is model-specific; human structural healing was not tested.
A local injection report described symptom benefit and called for imaging follow-up.
What it cannot establish: No concurrent control or verified faster structural healing; local administration is outside systemic scope.
Intact peptide cleared rapidly; intramuscular bioavailability differed by species.
What it cannot establish: Radiolabel distribution includes metabolites and does not establish human active-peptide exposure.
Participants reported symptom improvement following bladder-area injections.
What it cannot establish: Bladder symptoms, local delivery and no concurrent control do not test the prespecified tissues.
No adverse effects were reported during the short observation period.
What it cannot establish: Previously exposed adults and tiny sample cannot establish general safety or healing efficacy.
Histological effects were reported; combination treatment lacked additional benefit.
What it cannot establish: Endpoint-specific results should not be recast as universal biomechanical superiority.
Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.
Rat and dog Results and material-identification Methods: rapid intact-peptide elimination, species-specific IM bioavailability and separately synthesized tritiated material. Human exposure was not measured.
This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.
Selected full-text checks: 1; abstract checks: 10; metadata-only anchors: 0. Complete-paper examinations credited in this update: 0.
New enrichment: HSEF v5.3 causal distinctions. Archived scorecard schema: 5.4; retained as recorded.
PMID 14554208 · DOI 10.1016/S0736-0266(03)00110-4
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 15052688 · DOI 10.3748/wjg.v10.i7.1032
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 16583442 · DOI 10.1002/jor.20096
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 20225319 · DOI 10.1002/jor.21107
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 21030672 · DOI 10.1152/japplphysiol.00945.2010
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 29358856 · DOI 10.3748/wjg.v23.i48.8465
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 36588717 · DOI 10.3389/fphar.2022.1026182
Selected full-text passages checked. Rat and dog Results and material-identification Methods: rapid intact-peptide elimination, species-specific IM bioavailability and separately synthesized tritiated material. Human exposure was not measured.
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
PMID 42542926 · DOI 10.52312/jdrs.2026.2951
Selected abstract passages checked. Primary record and selected abstract passages checked; no complete-paper appraisal credited.
Read the dated addendum · Video script and storyboard insert · References (RIS) · References (BibTeX)